BioMarin Appoints Two BioPharmaceutical Veterans to Board

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
BioMarin Appoints Two BioPharmaceutical Veterans to Board of Directors, Willard Dere, M.D. and Kathryn E. Falberg

SAN RAFAEL, Calif., July 18, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ), a global leader in providing therapies for rare genetic diseases, today announced the appointment of two biopharmaceutical veterans to its Board of Directors: Willard Dere, M.D., Professor of Internal Medicine at the University of Utah Health Sciences Center and former Senior Vice President in Research and Development at Amgen and Kathryn E. Falberg, former Chief Financial Officer of Jazz Pharmaceuticals and Amgen.

“We are thrilled to have Dr. Dere and Ms. Falberg both join BioMarin’s Board of Directors.  They represent some of the most talented leaders in the biopharmaceutical industry and bring additional industry experience in drug development and finance to an already outstanding board,” said Jean-Jacques Bienaimé, Chairman and Chief Executive Officer at BioMarin.  “I am confident they will make meaningful contributions to support BioMarin through a transformative period of growth, as we continue to develop therapies to meet the unmet medical needs of patients with rare genetic diseases.”

“I am honored to serve on the board of a company that shares my passion for translating exciting science into important therapies to address unmet medical needs,” said Willard Dere, M.D. “I look forward to working with BioMarin to help further its efforts to deliver first-in-class and best-in-class therapies to treat patients with rare genetic diseases.”

“I admire BioMarin as a pioneer in developing therapies for rare disease patients and am delighted to become a member of the board,” said Kathryn E. Falberg.  “It is an exciting time to join the company, as it continues to build its current business, while advancing its robust pipeline during a time of exceptional growth.”

Dr. Dere and Ms. Falberg join Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, Lead Independent Director Richard Meier, International Executive Vice President and Chief Financial Officer, Owens & Minor, Inc., Michael Grey, President and Chief Executive Officer, Amplyx Pharmaceuticals, Inc., Elaine J. Heron, Ph.D., Director and former Chief Executive Officer, Amplyx Pharmaceuticals, Inc, V. Bryan Lawlis, President and Chief Executive Officer, Itero Biopharmaceuticals, LLC, Alan Lewis, Ph.D., Chief Executive Officer, DiaVacs, Inc., David Pyott, former Chief Executive Officer of Allergan plc. and Dennis J. Slamon, M.D., Ph.D., Professor of Medicine, UCLA Department of Medicine as BioMarin’s Board of Directors.

About Willard Dere, M.D.

Dr. Willard Dere is Professor of Internal Medicine; B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Executive Director of Personalized Health, and Co-Principal Investigator of the Center for Clinical and Translational Science at the University of Utah Health Sciences Center.  Prior to re-joining academia in November 2014, Dr. Dere was in the biopharmaceutical industry for 25 years.  He joined Amgen in 2003 where he held multiple roles including head of global development, international research and development, and both corporate and international chief medical officer.  He led the development programs for Prolia and several other programs, and retired from Amgen in October 2014.  He began his career at Eli Lilly in 1989, and held a number of different global roles in clinical pharmacology, regulatory affairs, and both early-stage translational, and late-stage clinical research.  While at Eli Lilly, he led the development of Evista and Forteo.  Since 2014, he has been a member of the Board of Directors for Radius Health and serves on the scientific advisory board of the California Institute of Regenerative Medicine.

Dr. Dere attended undergraduate and medical school at the University of California, Davis. He trained in internal medicine at the University of Utah and endocrinology/ metabolism at the University of California at San Francisco, and was on the Internal Medicine faculty at the University of Utah for 4 years during which time he was recognized annually with teaching awards.  He has published numerous articles; wrote and co-edited a primary care textbook; was awarded the 2008 transformational leadership award from his alma mater; and is a fellow in the American College of Physicians.

About Kathryn E. Falberg

Ms. Kathryn E. Falberg served as Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals plc, a multi-national specialty biopharmaceutical company, from March 2012 to March 2014 after serving as Senior Vice President and Chief Financial Officer since December 2009.  Her responsibilities at Jazz Pharmaceuticals included strategy, corporate development, corporate communications and information technology.  During this period, the company grew rapidly and completed a number of significant acquisitions and financing transactions.  From 2001 through 2009, Ms. Falberg worked with a number of smaller companies while serving as a corporate director and audit committee chair for several companies.  From 1995 to 2001, Ms. Falberg was with Amgen, a leading global biotechnology company, where she served as Senior Vice President, Finance and Strategy and Chief Financial Officer and prior to that as Vice President Chief Accounting Officer, and Vice President, Treasurer.  Ms. Falberg received an M.B.A. and B.A., in Economics from the University of California, Los Angeles and is a certified public accountant, inactive. 

Ms. Falberg also serves as a member of the board of directors for biopharmaceutical companies Medivation, Aimmune Therapeutics, and aTyr Pharma.  Ms. Falberg previously served on the board of directors of Halozyme Therapeutics, QLT, Human Genome Sciences, VISX, and Fresh del Monte. 

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates.  

For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin® is a registered trademarks of BioMarin Pharmaceutical Inc.

 

Contacts: Investors Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media Debra Charlesworth BioMarin Pharmaceutical Inc. (415) 455-7451

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
E-Rate Risk and Data Center Rules Demand Attention

Updated Category News Views 71

America’s digital plumbing is getting squeezed at both ends: the public connections nobody notices until they fail, and the industrial-scale computing boom everybody suddenly wants built yesterday. Connected Nation’s two bonus podcast episodes from the Broadband Nation Expo in New Orleans put those pressures side by side, and it is a more useful pairing than it may...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 51

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 95

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
ADFW 2026 Builds a Bigger Stage for Global Capital

Updated Category News Views 46

Abu Dhabi is not merely booking conference rooms this December; it is assembling a very deliberate display of financial muscle. Abu Dhabi Finance Week runs from 7 to 10 December 2026, and ADGM says its fifth edition will carry its largest-ever programme of partner-led activity. That is a promotional claim, sure, but the partner list is substantial enough that investors...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 97

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 99

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 175

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading
Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 60

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 57

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading

Top 5 Most Recently Viewed Articles

CHITA LIVING Showcases Stylish Furniture at Nashville Event

Updated Category News Views 333

CHITA LIVING Celebrates Style and Comfort at Nashville Event HOUSTON, Oct. 28, 2024 -- CHITA LIVING, a distinctive furniture company renowned for its stylish and inviting designs, is thrilled to be a part of Modern Luxury Nashville's exciting Announcement Party, happening soon at Diamond Creek Farms. This event showcases the perfect blend of comfort and elegance, a true...

Continue Reading
Buffy Payne Joins LifeKnight as Chief Security Officer

Updated Category News Views 236

Buffy Payne Joins LifeKnight as Chief Security Officer Expanding Global Safety Innovation Through AI-Driven Detection and Direction LifeKnight, Inc., a leader in AI-powered safety and health monitoring technology, has appointed Buffy Payne as Chief Security Officer (CSO). Bringing over three decades of experience in corporate security and crisis management, her role...

Continue Reading
Host Hotels & Resorts Achieves Remarkable Sustainability Milestone

Updated Category News Views 187

Host Hotels & Resorts Recognized for Sustainability Efforts Host Hotels & Resorts, Inc. (NASDAQ: HST), a leading name in the lodging real estate investment trust (REIT) sector, has made headlines once again. The company proudly announced its inclusion in the Dow Jones Sustainability World Index for the sixth year in a row, solidifying its reputation as a global...

Continue Reading
Toll Brothers Unveils New Luxury Community at The Pinehills

Updated Category News Views 220

Luxury Living in The Pinehills Community In a significant development for homebuyers, Toll Brothers, Inc. (NYSE:TOL), recognized as the leading builder of luxury homes in the nation, is excited to announce the opening of the Broadleaf community at The Pinehills. This luxurious community, designed with the discerning homeowner in mind, offers breathtaking new construction...

Continue Reading
Watts Water Technologies Faces Challenges but Sees Potential Growth

Updated Category News Views 330

Watts Water Technologies Reports Third Quarter Earnings Watts Water Technologies, Inc. (NYSE: WTS), a leader in providing water solutions globally, has announced its third-quarter results, marked by a blend of challenges and prospects for strategic advancements. CEO Bob Pagano, alongside CFO Shashank Patel and Senior VP Diane McClintock, discussed the company’s mixed...

Continue Reading